Sagimet Biosciences Inc. (SGMT) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
SGMT currently has 32.6M outstanding shares. with significant dilution risk as 121M authorized shares could dilute existing holders by 373.0%. The company has significantly diluted shareholders by 2024.69% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 12, 2026 |
10-Q filing | 32.6M shares outstanding |
33M | 120M |
| Mar 11, 2026 |
10-K filing | 32.3M shares outstanding |
32M | 120M |
| Nov 13, 2025 |
10-Q filing | 32.5M shares outstanding |
32M | 120M |
| Aug 13, 2025 |
10-Q filing | 32.2M shares outstanding |
32M | 120M |
| May 08, 2025 |
10-Q filing | 1.5M shares outstanding |
1.5M | 120M |
| Mar 12, 2025 |
10-K filing | 1.5M shares outstanding |
1.5M | 120M |
| Nov 14, 2024 |
10-Q filing | 32.1M shares outstanding |
32M | 120M |
| Aug 15, 2024 |
S-3 filing: The company is filing an S-3 to offer and sell up to $300,000,000 in the aggregate of Series A Common Stock, Preferred Stock , Debt Securities , Warrants , Units, and Subscription Rights from time to time in one or more offerings. |
30M | 120M |
| Aug 14, 2024 |
10-Q filing | 31.9M shares outstanding |
32M | 0 |
| May 15, 2024 |
10-Q filing | 29.0M shares outstanding |
29M | 0 |
| Mar 25, 2024 |
10-K filing | 30.4M shares outstanding |
30M | 0 |
| Jan 30, 2024 |
8-K filing: Sagimet Biosciences Inc. closed an underwritten public offering of 9,000,000 shares of Series A common stock at $12.50 per share, resulting in approximately $112.5 million of gross proceeds. ($112.5M proceeds) |
1.6B | 0 |
| Jan 24, 2024 |
S-1/A filing: This S-1/A filing updates the number of shares of common stock the Company is authorized to issue, increasing it from 1,590,550,754 to 1,608,370,000. |
1.6B | 0 |
| Nov 13, 2023 |
10-Q filing | 21.4M shares outstanding |
21M | 0 |
| Aug 21, 2023 |
10-Q filing | 0.2M shares outstanding |
190K | 0 |
| Jul 10, 2023 |
S-1/A filing: This S-1/A filing relates to an increase in the number of authorized shares of common stock from 1,590,550,754 to 1,608,370,000 and discusses potential issuances related to the conversion of redeemable convertible preferred stock, exercise of warrants, and exercise of stock options. |
N/A | 0 |
| Jul 03, 2023 |
S-1/A filing: The filing relates to an S-1/A filing for common stock, increasing the authorized shares from 1,590,550,754 to 1,608,370,000 and discussing reserved shares for potential conversion of redeemable convertible preferred stock, exercise of warrants and stock options. |
N/A | 0 |
| Jun 23, 2023 |
S-1 filing: S-1 filing for common stock offering, increasing authorized shares. |
N/A | 0 |
| Mar 21, 2022 |
RW filing: Sagimet Biosciences Inc. is withdrawing its Registration Statement on Form S-1 (File No. 333-255304) because it does not intend to proceed with the initial public offering of the common shares proposed to be registered at this time. |
N/A | 0 |
| May 10, 2021 |
S-1/A filing: This S-1/A filing relates to Sagimet Biosciences Inc.'s initial public offering of Class A common stock. |
N/A | 0 |
| Apr 16, 2021 |
S-1 filing: This S-1 filing relates to the initial public offering of Class A common stock by Sagimet Biosciences Inc. |
N/A | 0 |